Send Message
View as an RSS Feed
  • Amarin: A Physician's Perspective On Vascepa  [View article]
    DoctorX, as you are a physician, I would be very interested in your point by point analysis of today's Amarin article on SA by Alex Heisenberg. Specifically the medical issues he raises. Thanks.
    Feb 26, 2013. 05:49 AM | Likes Like |Link to Comment
  • Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made.  [View news story]
    fully agree with comments .. Amarin has an excellent future.. but curious as to why FDA would put off NCE decsion... odd
    Jan 21, 2013. 09:49 PM | Likes Like |Link to Comment
  • Hot Biotechs And Possible Shorting Opportunities  [View article]
    $AMRN has over $200 million on hand and less than $25 million quarterly burn rate.. dilution is a potential issue? really??
    Nov 22, 2012. 03:43 PM | 3 Likes Like |Link to Comment
  • 6 Gilded Stocks To Avoid  [View article]
    AMRN.. "its value is based on the speculation that Vascepa will sell very well" really? The superior efficacy, safety and and utility of this drug and well documented from multiple sources .. where is the speculation in that? Are your articles some sort of community college homework assignment?
    Nov 22, 2012. 02:44 PM | 2 Likes Like |Link to Comment